Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rallybio (RLYB) Common Equity (2023 - 2025)

Rallybio (RLYB) has disclosed Common Equity for 3 consecutive years, with $58.0 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 6.0% to $58.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.0 million through Dec 2025, down 6.0% year-over-year, with the annual reading at $58.0 million for FY2025, 6.0% down from the prior year.
  • Common Equity hit $58.0 million in Q4 2025 for Rallybio, down from $63.0 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $155.2 million in Q1 2023 to a low of $46.0 million in Q2 2025.
  • Historically, Common Equity has averaged $87.2 million across 3 years, with a median of $75.4 million in 2024.
  • Biggest five-year swings in Common Equity: tumbled 42.7% in 2024 and later dropped 6.0% in 2025.
  • Year by year, Common Equity stood at $106.2 million in 2023, then crashed by 41.94% to $61.7 million in 2024, then fell by 6.0% to $58.0 million in 2025.
  • Business Quant data shows Common Equity for RLYB at $58.0 million in Q4 2025, $63.0 million in Q3 2025, and $46.0 million in Q2 2025.